Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Kaku, Saito"'
Autor:
Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Tatsu Shimoyama, Keun-Wook Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara
Publikováno v:
Journal of Clinical Oncology. 41:816-825
PURPOSE To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)–low gastric or gastroesophageal junction (GEJ) adenocarcinoma. METHODS Patients with locally advanced or metastatic HER2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b635a45b7e777cde3581b657c6feb416
https://doi.org/10.1200/jco.22.00575
https://doi.org/10.1200/jco.22.00575
Autor:
Bob T. Li, Gilles Gallant, Takahiro Jikoh, Jasmeet Singh, Masahiro Sugihara, Kaku Saito, Trisha M. Wise-Draper, Kenji Tamura, Charles Redfern, Haeseong Park, Shunji Takahashi, Toshihiko Doi, Pasi A. Jänne, Ian Krop, Hiroji Iwata, Junji Tsurutani
Treatment-emergent adverse events (safety analysis set)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1717f7013cb7b86fc4d1d2d54fe7d4f9
https://doi.org/10.1158/2159-8290.22535039
https://doi.org/10.1158/2159-8290.22535039
Autor:
Bob T. Li, Gilles Gallant, Takahiro Jikoh, Jasmeet Singh, Masahiro Sugihara, Kaku Saito, Trisha M. Wise-Draper, Kenji Tamura, Charles Redfern, Haeseong Park, Shunji Takahashi, Toshihiko Doi, Pasi A. Jänne, Ian Krop, Hiroji Iwata, Junji Tsurutani
Inclusion and exclusion criteria for cohort 2d (advanced HER2-expressing non-breast/non-gastric or HER2-mutant solid tumors)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c197f14349d1f51509404ee158d621c0
https://doi.org/10.1158/2159-8290.22535036
https://doi.org/10.1158/2159-8290.22535036
Autor:
Bob T. Li, Gilles Gallant, Takahiro Jikoh, Jasmeet Singh, Masahiro Sugihara, Kaku Saito, Trisha M. Wise-Draper, Kenji Tamura, Charles Redfern, Haeseong Park, Shunji Takahashi, Toshihiko Doi, Pasi A. Jänne, Ian Krop, Hiroji Iwata, Junji Tsurutani
Mutation type and confirmed response for 19 patients with HER2-mutated tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab9b9738f44a536695f95b572de7ade
https://doi.org/10.1158/2159-8290.22535042.v1
https://doi.org/10.1158/2159-8290.22535042.v1
Autor:
Bob T. Li, Gilles Gallant, Takahiro Jikoh, Jasmeet Singh, Masahiro Sugihara, Kaku Saito, Trisha M. Wise-Draper, Kenji Tamura, Charles Redfern, Haeseong Park, Shunji Takahashi, Toshihiko Doi, Pasi A. Jänne, Ian Krop, Hiroji Iwata, Junji Tsurutani
HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1eba60d6f3b4018f9801e8a6c4da62f
https://doi.org/10.1158/2159-8290.c.6547745.v1
https://doi.org/10.1158/2159-8290.c.6547745.v1
Autor:
Bob T. Li, Gilles Gallant, Takahiro Jikoh, Jasmeet Singh, Masahiro Sugihara, Kaku Saito, Trisha M. Wise-Draper, Kenji Tamura, Charles Redfern, Haeseong Park, Shunji Takahashi, Toshihiko Doi, Pasi A. Jänne, Ian Krop, Hiroji Iwata, Junji Tsurutani
Interstitial lung disease monitoring and management
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::749b84b6d783e829481711ef7e43759e
https://doi.org/10.1158/2159-8290.22535045
https://doi.org/10.1158/2159-8290.22535045
Autor:
Aguinaldo Bezerra, Ivanovitch Silva, Luiz Affonso Guedes, Diego Silva, Gustavo Leitão, Kaku Saito
Publikováno v:
Sensors, Vol 19, Iss 12, p 2772 (2019)
Alarm and event logs are an immense but latent source of knowledge commonly undervalued in industry. Though, the current massive data-exchange, high efficiency and strong competitiveness landscape, boosted by Industry 4.0 and IIoT (Industrial Interne
Externí odkaz:
https://doaj.org/article/2457e5fe33874b388ef98a5511501b0c
Publikováno v:
Folia Pharmacologica Japonica. 156:47-51
Antibody-drug conjugates (ADCs) combine the specific antibody and cytotoxic agent by a linker and represent a promising drug class with a wider therapeutic window than conventional chemotherapeutic agents by substantiating efficient and specific drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb8a7438450ede43673503e32fe4bad6
https://doi.org/10.1254/fpj.20076
https://doi.org/10.1254/fpj.20076
Autor:
Kohei Shitara, Hisato Kawakami, Jeeyun Lee, DESTINY-Gastric Investigators, Hyun-Cheol Chung, Akihito Kojima, Daisuke Sakai, Min-Hee Ryu, Masahiro Sugihara, Kensei Yamaguchi, Hiroshi Yabusaki, Satoru Iwasa, Takahiro Kamio, Naotoshi Sugimoto, Yung-Jue Bang, Yoshinori Kawaguchi, Kaku Saito
Publikováno v:
New England Journal of Medicine. 382:2419-2430
Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate consisting of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. The drug may have efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67a4ef70fcc265e12aac9a6282d216c1
https://doi.org/10.1056/nejmoa2004413
https://doi.org/10.1056/nejmoa2004413
Autor:
Marcos Muniz Calor Filho, Kaku Saito, Luiz Affonso Henderson Guedes De Oliveira, Danilo Curvelo De Souza, Gustavo Bezerra Paz Leitão, Ivanovitch Medeiros Dantas Da Silva, Celi Beatriz Costa Lope, Diego Rodrigues Medeiros, Júlia Guardiani, Lucas Torres Marques
Publikováno v:
Rio Oil and Gas Expo and Conference. 22:191-192
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36b378babc31bb6433cc80765e621578
https://doi.org/10.48072/2525-7579.rog.2022.191
https://doi.org/10.48072/2525-7579.rog.2022.191